Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region.
The EASL Recommendations on Treatment of Hepatitis C Webinar is intended to assist physicians and other healthcare providers, in the clinical decision-making process, by describing the current optimal management of patients with acute and chronic HCV infections.
Join us on 26 January 2021 at 18:00 CET for this live webinar.
Live Webinar Faculty
- Thomas Berg, University of Leipzig, Leipzig, Germany
- Jean-Michel Pawlotsky, University of Paris-Est, Paris, France
- Marina Berenguer, La Fe University and Polytechnic Hospital, Valencia, Spain
- Geoffrey Dusheiko, University College London School of Medicine, London, United-Kingdom
- Francesco Negro, University Hospital of Geneva, Geneva, Switzerland
- Fiona Marra, University of Liverpool, Liverpool, United-Kingdom
- Olav Dalgard, Akershus University Hospital, Lørenskog, Norway
- Heiner Wedemeyer, The Hannover Medical School, Hannover, Germany
- Alessio Aghemo, Humanitas Research Hospital, Milan, Italy
- Massimo Puoti, The Ospedale Maggiore Policlinico of Milan, Milan, Italy
|18:00-18:15||Presentation of the new EASL Recommendations
|18:20-18:25||Children and pregnant women
|18:25-18:30||PWID and prisoners
|18:30-18:35||Organ (including liver) transplant setting
|18:40-18:45||Recently acquired hepatitis C
|18:45-18:50||Treatment failures and retreatment
Who should attend?
- Health care professionals
- General HCV-treatment practitioners